Squarepoint
FOMX

Squarepoint’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Squarepoint’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,111
Closed -$43K – 2569
2018
Q4 		$43K Sell
12,111
-82,538
-87% -$359K ﹤0.01% 1850
2018
Q3 		$542K Buy
+94,649
New +$541K 0.01% 1263

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Squarepoint's FOMX Position: Q1 2019 in Review

Squarepoint sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2019, closing a stake of 12,111 shares — an estimated $43K sold.

Squarepoint first reported a position in FOMX in Q3 2018 and held it in 2 quarters. The position peaked at $542K in Q3 2018. 62 funds tracked by Wall St. Rank hold FOMX as of Q1 2019.

  • Squarepoint reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Squarepoint sold 12,111 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2019, an estimated $43K.
  • Squarepoint first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2018 and held it in 2 quarters.
  • Squarepoint's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $542K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2019.

Based on Squarepoint's 13F filing for Q1 2019, filed 15 May 2019.